CL2020002139A1 - Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado. - Google Patents

Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.

Info

Publication number
CL2020002139A1
CL2020002139A1 CL2020002139A CL2020002139A CL2020002139A1 CL 2020002139 A1 CL2020002139 A1 CL 2020002139A1 CL 2020002139 A CL2020002139 A CL 2020002139A CL 2020002139 A CL2020002139 A CL 2020002139A CL 2020002139 A1 CL2020002139 A1 CL 2020002139A1
Authority
CL
Chile
Prior art keywords
treatment
liver cancer
prevention
derivatives
compounds
Prior art date
Application number
CL2020002139A
Other languages
English (en)
Inventor
Thomas Poeschinger
Carola Ries
Hong Shen
Hongying Yun
Sabine Hoves
Carina Hage
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2020002139A1 publication Critical patent/CL2020002139A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), en donde R1, R2 y R3 son como se describen en el presente documento, y sus profármacos o una sal farmacéuticamente aceptable, enantiómero o diastereómero de la misma, para (su uso en) el tratamiento y/o profilaxis del cáncer de hígado.
CL2020002139A 2018-02-28 2020-08-19 Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado. CL2020002139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2018077501 2018-02-28

Publications (1)

Publication Number Publication Date
CL2020002139A1 true CL2020002139A1 (es) 2021-01-04

Family

ID=65685310

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002139A CL2020002139A1 (es) 2018-02-28 2020-08-19 Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.

Country Status (19)

Country Link
EP (1) EP3758707A1 (es)
JP (1) JP7089596B2 (es)
KR (1) KR20200128414A (es)
CN (1) CN111801100B (es)
AR (1) AR114419A1 (es)
AU (1) AU2019228654A1 (es)
BR (1) BR112020016509A2 (es)
CA (1) CA3091950A1 (es)
CL (1) CL2020002139A1 (es)
CO (1) CO2020010306A2 (es)
IL (1) IL276817A (es)
MA (1) MA52412A (es)
MX (1) MX2020008746A (es)
PE (1) PE20211456A1 (es)
PH (1) PH12020551343A1 (es)
RU (1) RU2020131012A (es)
SG (1) SG11202008291XA (es)
TW (1) TW202003518A (es)
WO (1) WO2019166432A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912715B2 (en) 2016-08-29 2024-02-27 Novartis Ag Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
US12071441B2 (en) 2018-02-28 2024-08-27 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102409595B1 (ko) 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CN112420196A (zh) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 急性心肌梗死患者5年内生存率的预测方法和系统
EP4554678A1 (en) * 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Phosphorylpurinone compounds for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
CA2760766A1 (en) * 2009-05-21 2010-11-25 Nicholas James Bennett Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
SG10201406813RA (en) * 2009-10-22 2014-11-27 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
CA2802733C (en) * 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
AU2011289234B2 (en) * 2010-08-13 2014-09-11 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
NZ775222A (en) * 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
IL284255B (en) * 2016-08-29 2022-07-01 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
TWI720250B (zh) * 2016-09-13 2021-03-01 瑞士商赫孚孟拉羅股份公司 利用tlr7促效劑及hbv蛋白殼組裝抑制劑之組合治療

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912715B2 (en) 2016-08-29 2024-02-27 Novartis Ag Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
US12071441B2 (en) 2018-02-28 2024-08-27 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza

Also Published As

Publication number Publication date
EP3758707A1 (en) 2021-01-06
CA3091950A1 (en) 2019-09-06
PE20211456A1 (es) 2021-08-05
JP7089596B2 (ja) 2022-06-22
BR112020016509A2 (pt) 2020-12-15
TW202003518A (zh) 2020-01-16
CN111801100B (zh) 2023-10-24
CO2020010306A2 (es) 2020-08-31
AR114419A1 (es) 2020-09-02
CN111801100A (zh) 2020-10-20
AU2019228654A1 (en) 2020-09-03
SG11202008291XA (en) 2020-09-29
JP2021514972A (ja) 2021-06-17
IL276817A (en) 2020-10-29
KR20200128414A (ko) 2020-11-12
MA52412A (fr) 2021-06-02
PH12020551343A1 (en) 2021-06-21
MX2020008746A (es) 2020-09-28
RU2020131012A (ru) 2022-03-28
WO2019166432A1 (en) 2019-09-06

Similar Documents

Publication Publication Date Title
MX379474B (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
MX394700B (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
CO2017009994A2 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
CR20170003A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CU20170007A7 (es) Compuestos de imidazopiridazina
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
ECSP16083017A (es) Derivados de diheterociclo enlazado a cicloalquilo
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos
SV2016005317A (es) Derivados de pirrolidina -2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
CR20160532A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1